| Chronic Lymphocytic Leukemia |
1 |
1 |
| Biologic Therapy |
0 |
0.84 |
| Tyrosine Kinase Inhibitor |
0 |
0.81 |
| Tyrosine Kinase |
0 |
0.61 |
| Toxicology |
0 |
0.44 |
| Pharmacokinetics |
0 |
0.31 |
| Mantle Cell Lymphoma |
0 |
0.26 |
| Waldenstrom Macroglobulinemia |
0 |
0.24 |
| Cancer |
0 |
0.23 |
| Leukemia |
0 |
0.23 |
| Lymphoma |
0 |
0.23 |
| Patient Safety |
0 |
0.18 |
| Adverse Effects |
0 |
0.15 |
| Clinical Guidelines |
0 |
0.15 |
| Atrial Fibrillation |
0 |
0.09 |
| Healthcare and Medical Technology |
0 |
0.09 |
| Calcaneal |
0 |
0.08 |
| Clinical Research |
0 |
0.08 |
| Hematology |
0 |
0.08 |
| Pennsylvania |
0 |
0.08 |
| Refractory |
0 |
0.08 |